Stada has announced the appointment of Erin Federman as vice-president and global commercial head of its biosimilars business. Federman, who Stada describes as being “widely recognized within the industry as a passionate advocate of the access and affordability advantages enabled by biosimilar competition,” is coming to the company from Novo Nordisk, where she has most recently acted as global marketing and project vice-president for the group’s $8bn insulins portfolio.
Who’s Hired? Stada Appoints New Biosimilars Head
Erin Federman Will Be Responsible For Global Biosimilars Portfolio And Pipeline
Stada has welcomed former Novo Nordisk executive Erin Federman into its ranks as she steps into the role of global commercial head of biosimilars. Organizations such as the Association for Accessible Medicines, Granules India, Synthon, Taro and Mayne have also appointed new senior staff members in recent months.
